Professional
Medical Education Webinar Series

ENRICH: A Novel Approach to Clinical Trials in ICH

Wednesday, March 1st, 2023 • 6:00pm EST

The ENRICH Trial has completed enrollment and many are anxiously awaiting the results. As ENRICH is the FIRST adaptive clinical trial designed with enrichment based on hemorrhage location, there are several questions surrounding this unique structure and how proper interpretation of results is essential for understanding the level of impact the data may provide. Are you curious to know:

Why is trial design so important?

How is ENRICH different from other ICH trials?

Without p-values, how should data be interpreted?

Join an expert in novel **Bayesian adaptive design and analysis,** Dr. Ben Saville, PhD as he discusses key aspects of the ENRICH randomized adaptive clinical trial including population enrichment, flexible sample size, and why primary results will be presented without p-values.

ENRICH
www.ENRICHtrial.com

REGISTER TODAY

Click or Scan

Benjamin R. Saville, PhD
Berry Consultants, LLC
Director, Trial Design & Analysis
Senior Statistical Scientist

Ben Saville specializes in the design of innovative Bayesian adaptive clinical trials, working primarily with medical device companies, pharmaceutical companies, and academic investigators. Through his work to solve challenging problems via Bayesian adaptive platform trial designs and related topics, Dr. Saville has authored approximately 100 peer-reviewed publications in the statistical and medical literature.

PROGRAM AGENDA

Novel Adaptive Clinical Trials
Landmark trials influencing patient care through adaptive design

What Makes ENRICH Different
Novel Bayesian adaptive design
Flexible sample size
Population enrichment
Innovative primary endpoint measure

Interim Adaptations
Advantages of population enrichment by hemorrhage location

Bayesian Probabilities Instead of p-values
Understanding the results of ENRICH

Q&A

Questions?